Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

On Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported lower-than-expected first-quarter 2025 earnings. Vertex reported first-quarter adjusted earnings per share of $4.06 ...

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion.

Vertex Pharmaceuticals reported disappointing Q1 revenue and earnings. The company also revealed it is temporarily pausing part of a phase 1/2 study of experimental cystic fibrosis drug VX-522.

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.68% to $432.00 Tuesday, on what proved to be an all-around mixed trading ...

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $4.06 per share for the first quarter of 2025, missing ...

In trading on Tuesday, shares of Vertex Pharmaceuticals, Inc. (Symbol: VRTX) entered into oversold territory, hitting an RSI reading of 28.4, after changing hands as low as $431.65 per share.

Investors eye Vertex’s Q1 for Alyftrek and Journavx momentum amid Trikafta’s international headwinds. Vertex stock shows a bullish technical bias despite recent pullback and mixed short-term ...

Vertex Pharmaceuticals VRTX will release its quarterly earnings report on Monday, 2025-05-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Vertex ...

Access detailed historical stock prices, including daily closing prices, for VRTX. Analyze past performance trends, track price movements, and explore historical data to inform your investment ...